

From: [Katelyn O'Reilly](#)
To: [Chevalier, Charles H.](#); [Liza Walsh](#)
Cc: [Lauren Malakoff](#); [Caracappa, Michael V.](#)
Subject: RE: 2:25-cv-03179-ES-JRA: HALOZYME, INC. v. MERCK SHARP & DOHME CORP.
Date: Tuesday, May 13, 2025 1:53:17 PM
Attachments: [~WRD3347.jpg](#)
[Halozyyme-Merck - Stip. Substituting Party Waiving Service Setting Answer Date - WPOF edits.docx](#)

External Email: Use caution with links and attachments.

Hi Charles,

Thank you for the email and for your patience as we ran this down with our team. We had one minor edit to the stipulation, which is in redline in the attached. Please let us know if this is acceptable, and if so, whether you will be filing with the Court or prefer we do so.

Best,

Katelyn

From: Chevalier, Charles H. <CChevalier@gibbonslaw.com>

Sent: Friday, May 9, 2025 11:43 AM

To: Liza Walsh <LWalsh@walsh.law>

Cc: Katelyn O'Reilly <KOREilly@walsh.law>; Lauren Malakoff <LMalakoff@walsh.law>; Caracappa, Michael V. <MCaracappa@gibbonslaw.com>

Subject: RE: 2:25-cv-03179-ES-JRA: HALOZYME, INC. v. MERCK SHARP & DOHME CORP.

Dear Liza,

Thank you for calling me last night to discuss the complaint in the above-referenced matter. As I informed you Merck Sharp & Dohme Corp. does not exist. In the Spring of 2022 Merck Sharp & Dohme Corp. merged with and into Merck Sharp & Dohme LLC. Merck Sharp & Dohme LLC is the only surviving entity stemming from that merger. Therefore, the complaint was filed against the wrong entity. Likewise, service was ineffective.

Recognizing that, we think the simplest path forward is a substitution of the correct entity, Merck Sharp & Dohme LLC, for the incorrect entity, Merck Sharp & Dohme Corp. To accomplish that, we have prepared the attached stipulation that also addresses service and the time Merck Sharp & Dohme LLC has to respond to the complaint. At your convenience would you kindly let us know if Halozyyme agrees to proceed with the stipulation. I look forward to your response.

Kind regards,

Charles

CHARLES H. CHEVALIER | Director
Intellectual Property Group
t: 973-596-4611 | c: 201-259-6938 | f: 973-639-6263
cchevalier@gibbonslaw.com | [bio](#)

Gibbons P.C. | One Gateway Center | Newark, NJ 07102-5310
m: 973-596-4500 | f: 973-596-0545 | [office](#) | [map](#)



gibbonslaw.com | gibbonslawalert.com 

From: Chevalier, Charles H.
Sent: Thursday, May 8, 2025 4:37 PM
To: Liza M. Walsh - Walsh Pizzi O'Reilly Falanga LLP (lwalsh@walsh.law)
<LWalsh@walsh.law>
Cc: 'koreilly@walsh.law' <koreilly@walsh.law>; 'lmalakoff@walsh.law'
<lmalakoff@walsh.law>
Subject: Case 2:25-cv-03179

Hi Liza,

I hope all is well with you. At your convenience would you (or Katelyn or Lauren) kindly give me a call at my cell number below to discuss the attached complaint. I look forward to hearing from you.

Kind regards,

Charles

CHARLES H. CHEVALIER | Director
Intellectual Property Group
t: 973-596-4611 | c: 201-259-6938 | f: 973-639-6263
cchevalier@gibbonslaw.com | [bio](#)

Gibbons P.C. | One Gateway Center | Newark, NJ 07102-5310
m: 973-596-4500 | f: 973-596-0545 | [office](#) | [map](#)



gibbonslaw.com | gibbonslawalert.com 

Disclaimer

The contents of this message, together with any attachments, may contain information that is legally

privileged, confidential and exempt from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination, distribution, printing, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please do not read this message or any attachments and please notify me immediately by reply e-mail or call Gibbons P.C. at 973-596-4500 and delete this message, along with any attachments, from your computer.

The information contained in this message, including any attached documentation, may be CONFIDENTIAL and is for the intended addressee(s) only. Any unauthorized use, dissemination of the information, or copying of this message (or attachments) is prohibited. If you are not an intended addressee, please notify the sender immediately and delete this message.